Volume 388, Issue 10056, Pages (October 2016)

Slides:

Advertisements

Similar presentations

Adjuvant bisphosphonate treatment in early breast cancer: meta-analyses of individual patient data from randomised trials The Lancet Volume 386, Issue.

Advertisements

Crohn's disease Prof Daniel C Baumgart, MD, Prof William J Sandborn, MD The Lancet Volume 380, Issue 9853, Pages (November 2012) DOI: /S (12)

Volume 387, Issue 10037, Pages (June 2016)

Volume 390, Issue 10101, Pages (September 2017)

Volume 379, Issue 9824, Pages (April 2012)

Volume 92, Issue 2, Pages (December 2010)

Efficacy and safety of recombinant human parathyroid hormone (1–84) in hypoparathyroidism (REPLACE): a double-blind, placebo-controlled, randomised, phase.

Volume 380, Issue 9846, Pages (September 2012)

Volume 357, Issue 9273, Pages (June 2001)

Volume 364, Issue 9440, Pages (September 2004)

Volume 16, Issue 8, Pages (August 2017)

Volume 367, Issue 9517, Pages (April 2006)

Volume 375, Issue 9729, Pages (May 2010)

Volume 357, Issue 9257, Pages (March 2001)

Volume 359, Issue 9322, Pages (June 2002)

Volume 17, Issue 12, Pages (December 2016)

Pharmacogenetics and future drug development and delivery

Volume 349, Issue 9057, Pages (April 1997)

Volume 12, Issue 11, Pages (October 2011)

Volume 11, Issue 4, Pages (April 2012)

Volume 378, Issue 9785, Pages (July 2011)

Volume 376, Issue 9734, Pages (July 2010)

Volume 372, Issue 9633, Pages (July 2008)

Volume 383, Issue 9936, Pages (June 2014)

Intravenous or nebulised magnesium sulphate versus standard therapy for severe acute asthma (3Mg trial): a double-blind, randomised controlled trial

Volume 5, Issue 4, Pages (April 2006)

Evaluation of early administration of simvastatin in the prevention and treatment of delirium in critically ill patients undergoing mechanical ventilation.

Volume 371, Issue 9611, Pages (February 2008)

Volume 376, Issue 9734, Pages (July 2010)

Volume 13, Issue 3, Pages (March 2012)

Volume 372, Issue 9633, Pages (July 2008)

Volume 366, Issue 9486, Pages (August 2005)

Volume 16, Issue 8, Pages (August 2017)

Effect of intravenous haloperidol on the duration of delirium and coma in critically ill patients (Hope-ICU): a randomised, double-blind, placebo-controlled.

Mannose-binding lectin deficiency and disease severity in non-cystic fibrosis bronchiectasis: a prospective study Dr James D Chalmers, MBChB, Brian J.

Volume 379, Issue 9816, Pages (February 2012)

Volume 388, Issue 10061, Pages (December 2016)

Volume 3, Issue 2, Pages (February 2016)

Volume 2, Issue 12, Pages (December 2015)

Volume 372, Issue 9642, Pages (September 2008)

Volume 9, Issue 10, Pages (October 2008)

Volume 10, Issue 4, Pages (April 2011)

Montelukast for postinfectious cough in adults: a double-blind randomised placebo- controlled trial Dr Kay Wang, DPhil, Surinder S Birring, MD, Kathryn.

Incident diabetes in clinical trials of antihypertensive drugs

Misoprostol for small bowel ulcers in patients with obscure bleeding taking aspirin and non-steroidal anti-inflammatory drugs (MASTERS): a randomised,

Safety and immunogenicity of a parenteral P2-VP8-P[8] subunit rotavirus vaccine in toddlers and infants in South Africa: a randomised, double-blind, placebo-controlled.

Volume 375, Issue 9732, Pages (June 2010)

Volume 379, Issue 9812, Pages (January 2012)

Volume 12, Issue 6, Pages (June 2013)

Volume 378, Issue 9785, Pages (July 2011)

Tadalafil in patients with chronic obstructive pulmonary disease: a randomised, double- blind, parallel-group, placebo-controlled trial Dr Andrew R Goudie,

Volume 386, Issue 10011, Pages (December 2015)

Confessions of a journal junkie

Volume 372, Issue 9647, Pages (October 2008)

Intravenous or nebulised magnesium sulphate versus standard therapy for severe acute asthma (3Mg trial): a double-blind, randomised controlled trial

Volume 371, Issue 9627, Pages (May 2008)

Volume 3, Issue 2, Pages (February 2016)

Volume 16, Issue 15, Pages (November 2015)

Volume 15, Issue 13, Pages (December 2014)

Volume 16, Issue 15, Pages (November 2015)

Neuromuscular electrical stimulation to improve exercise capacity in patients with severe COPD: a randomised double-blind, placebo-controlled trial Dr.

Primary prophylaxis of cryptococcal disease with fluconazole in HIV-positive Ugandan adults: a double-blind, randomised, placebo-controlled trial Dr.

Safety and immunogenicity of an oral, replicating adenovirus serotype 4 vector vaccine for H5N1 influenza: a randomised, double-blind, placebo-controlled,

Volume 376, Issue 9737, Pages (July 2010)

Volume 5, Issue 1, Pages (January 2018)

Volume 368, Issue 9541, Pages (September 2006)

Efficacy and safety of lumacaftor/ivacaftor combination therapy in patients with cystic fibrosis homozygous for Phe508del CFTR by pulmonary function subgroup:

Volume 383, Issue 9930, Pages (May 2014)

Volume 371, Issue 9611, Pages (February 2008)

Volume 18, Issue 6, Pages (June 2019)

Presentation transcript:

Volume 388, Issue 10056, Pages 2153-2163 (October 2016) Adjunctive everolimus therapy for treatment-resistant focal-onset seizures associated with tuberous sclerosis (EXIST-3): a phase 3, randomised, double-blind, placebo- controlled study Dr Prof Jacqueline A French, MD, John A Lawson, MD, Prof Zuhal Yapici, MD, Hiroko Ikeda, MD, Tilman Polster, MD, Rima Nabbout, MD, Prof Paolo Curatolo, MD, Prof Petrus J de Vries, PhD, Dennis J Dlugos, MD, Noah Berkowitz, MD, Maurizio Voi, MD, Severine Peyrard, MS, Diana Pelov, MS, Prof David N Franz, MD The Lancet Volume 388, Issue 10056, Pages 2153-2163 (October 2016) DOI: 10.1016/S0140-6736(16)31419-2 Copyright © 2016 Elsevier Ltd Terms and Conditions

Figure 1 Trial profile AEDs=antiepileptic drugs. *A patient could have had multiple reasons for screen failure. †Everolimus trough concentrations. The Lancet 2016 388, 2153-2163DOI: (10.1016/S0140-6736(16)31419-2) Copyright © 2016 Elsevier Ltd Terms and Conditions

Figure 2 Seizure outcomes (A) Response rate by treatment group. Bars represent 95% CIs. (B) Median percentage reduction in seizure frequency by treatment group. Bars represent 95% CIs. (C) Distribution of reduction from baseline in seizure frequency by treatment group. (D) Response rate among various seizure types. Numbers on the x axis denoxste the number of patients with at least one occurrence of the seizure type during the baseline phase; bars represent 95% CIs. (E) Median percentage change from baseline in seizure frequency. (F) Median percentage of seizure-free days. The Lancet 2016 388, 2153-2163DOI: (10.1016/S0140-6736(16)31419-2) Copyright © 2016 Elsevier Ltd Terms and Conditions